Pregnancy in women with pulmonary arterial hypertension (PAH) is considered to be
associated with prohibitive maternal mortality. During the past decade, new advanced …

Pulmonary arterial hypertension (PAH) is a common complication of congenital heart
disease (CHD), with most cases occurring in patients with congenital cardiac shunts. In …

Pulmonary hypertension is associated with diverse cardiac, pulmonary, and systemic
diseases in neonates, infants, and older children and contributes to significant morbidity and …

Aims Mortality in adults with congenital heart disease is known to be increased, yet its extent
and the major mortality risks are unclear. Methods and results The Dutch CONCOR national …

Eisenmenger syndrome (ES), the most advanced form of pulmonary arterial hypertension
(PAH) associated with congenital heart disease, is a devastating condition that has a …

Aims To evaluate the efficacy of combining the dual endothelin receptor antagonist,
bosentan, and the phosfodiesterase-5-inhibitor, sildenafil, in patients with Eisenmenger …

A large proportion of patients with congenital heart disease (CHD), in particular those with
relevant systemic-to-pulmonary shunts, will develop pulmonary arterial hypertension (PAH) …

OBJECTIVES: The aim of the present study was to evaluate the safety, tolerability, clinical
and haemodynamic impact of add-on sildenafil in patients with congenital heart disease …

Pulmonary arterial hypertension (PAH) associated with congenital heart disease remains a
major problem despite advances in cardiac surgery. Recently, advanced therapies for PAH …

Objectives To examine long-term efficacy of disease targeting therapies (DTT) in patients
with Eisenmenger syndrome. Methods All adult patients with Eisenmenger syndrome treated …